Comparing patient access to pharmaceuticals in the UK and US

Applied Health Economics and Health Policy

Volumn 5, Issue 3, 2006, Pages 177-187

  Cohen, Joshua ^a,b   Cairns, Catherine ^a   Paquette, Cherie ^a   Faden, Laura ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BETA INTERFERON; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GENERIC DRUG; GLATIRAMER; OSELTAMIVIR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIVASTIGMINE; DRUG;

ALZHEIMER DISEASE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH SURVEY; HUMAN; INFLUENZA; MEDICARE; MENTAL DISEASE; MULTIPLE SCLEROSIS; OBESITY; OSTEOPOROSIS; PAIN; PHARMACOECONOMICS; PHARMACY; PRESCRIPTION; REIMBURSEMENT; RHEUMATOID ARTHRITIS; UNITED KINGDOM; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH INSURANCE; LEGAL ASPECT; MARKETING; NATIONAL HEALTH SERVICE; PHARMACY AND THERAPEUTICS COMMITTEE; PUBLICATION; STANDARD; STATISTICS; TIME;

COST-BENEFIT ANALYSIS; DRUG APPROVAL; FORMULARIES; GOVERNMENT AGENCIES; GREAT BRITAIN; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MARKETING; MEDICARE; PHARMACEUTICAL PREPARATIONS; PHARMACY AND THERAPEUTICS COMMITTEE; REIMBURSEMENT MECHANISMS; STATE MEDICINE; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34347264848     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200605030-00004     Document Type: Article

References (39)

1. PDUFA, FDA and stakeholders public meeting [online]. Available from URL: http://www.fda.gov/ohrms/dockets/05n0410/05n-0410-tr0001-vol2.pdf [Accessed 2006 Mar 24]
2. Towse A. The efficient use of pharmaceuticals: does Europe have lessons for the Medicare drug benefit. Health Aff (Millwood) 2003; 22 (3): 42-5
3. Civitas. Are the NHS reforms working? NHS: is the extra money working? 2003 [online]. Available from URL: http://www. civitas.org.uk/nhs/nhsMoney.php [Accessed 2005 Apr 2]
4. Laschober MA, Kitchman M, Neuman P, et al. Trends in Medicare supplemental insurance and prescription drug coverage, 1996-1999. Health Aff Web Exclusive 2002 Feb 27; 2002 [online]. Available from URL: http://content. healthaffairs.org/cgi/reprint/hlthaff.w2.127v1?.maxtoshow=&HITS=10&hits= 10& [Accessed 2005 Feb 27]
5. Medicare prescription drug benefit. Kaiser Family Foundation. March, 2005 [online]. Available from URL: http://www.kf f.org/medicare/upload/The-Medicare- Prescription-Drug-Benefit-Fact-Sheet.pdf [Accessed 2005 Apr 2]
6. General principles: FDA-EMEA parallel scientific advice meetings [online]. Available from URL: http://www.emea.eu.int/pdfs/general/direct/ internationalcoop/emea-fdascientificadvice.pdf [Accessed 2006 May 11]
7. Dickson M, J Hurst, S Jacobzone. Survey of pharmacoeconomic assessment activity in eleven countries. OECD working paper [online]. Available from URL: http://www.oecd.org/dataoecd/27/25/2955828.pdf [Accessed 2006 May 10]
8. Barbour V. Imatinib for chronic myeloid leukaemia: a NICE mess. Lancet 2001 Nov 3; 358 (9292): 1478
9. UK insurers 'pay only for NICE-backed drugs'. Pharma Marketletter 2005 Oct 17; 32 (41): 11
10. Towse A, Pritchard C. National Institute for Clinical Excellence (NICE): is economic appraisal working? Pharmacoeconomics 2002; 20 Suppl. 3: 95-105
11. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004 May; 13 (5): 437-52
12. Harris A, Buxton M, O'Brien B, et al. Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries. Expert Rev Pharmacoeconomics Outcomes Res 2001 Jul; 1 (1): 7-12
13. Buxton M. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE). Value Health 2001 May-Jun; 4 (3): 212-6
14. House of Commons Health Committee: NHS charges - third report of session 2005-06 [online]. Available from URL: http://www.publications.parliament.uk/pa/ cm200506/cmselect/cmhealth/815/815ii.pdf [Accessed 2006 May 11]
15. Syrett K. A technocratic fix to the 'legitimacy problem'? The Blair Government and health care rationing in the United Kingdom. J Health Polit Policy Law 2003; 28: 715-46
16. Cohen J. PBMs and a Medicare drug benefit. Food Drug Law J 2000; 55: 311-20
17. Kreling D. Cost control for prescription drug programs: pharmacy benefit manager (PBM) efforts, effects, and implications [online]. Available from URL: http://aspe.hhs.gov/health/re-ports/ drug-papers/kreling-final.htm [Accessed 2006 May 5]
18. Academy of Managed Care Pharmacy. The AMCP format for formulary submissions. Version 2.1, April 2005. A format for submission of clinical and economic data in support of formulary consideration by health care systems in the United States [online]. Available from URL: http://www.209.35.33.5/data/ resource/Format~Version_2_1~Final_Final.pdf [Accessed 2005 May 5]
19. Fox DM. Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions. Health Aff (Millwood) 2005 Jan-Feb; 24 (1): 114-22
20. Blue Cross Blue Shield technology evaluation center [online]. Available from URL: http://www.bcbs.com/tec/index.html [Accessed 2005 Apr 13]
21. Procedure for producing guidance documents describing Medicare's coverage process. Fed Reg 2004 Sep 24; 69 (185): 57325-6 [online]. Available from URL: http://www.cms.hhs.gov/coverage [Accessed 2005 May 19]
22. Drug Effectiveness Review Project. Center for Evidence Based Policy. Oregon Health & Science University [online]. Available from URL: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm [Accessed 2005 Apr 12]
23. Drug class reviews. Strategic Healthcare Group. Pharmaceutical benefits management. U.S. Department of Veterans Affairs [online]. Available from URL: http://www.vapbm.org/pbm/reviews.htm [Accessed 2005 Apr 21]
24. NICE home page [online]. Available from URL: http://www.nice.org.uk [Accessed 2005 Apr 4]
25. Find a Medicare prescription drug plan [online]. Available from URL: http://www.medicare.gov [Accessed 2006 Feb 2]
26. PBM National Formulary [online]. Available from URL: http://www1.va.gov/ health [Accessed 2006 Jan 31]
27. Drug coverage and pricing [online]. Available from URL: https://www.advancerx.com [Accessed 2006 Feb 3]
28. Hoadley J, Hargrave E, Cubanski J, et al. An in-depth examination of formularies and other features of Medicare drug plans [online]. Available from URL: http://www.kff.org/medicare/7489.cfm [Accessed 2006 May 11]
29. April 2005 payment allowance limits for Medicare Part B drug [online]. Available from URL: http://www.wpsic.com/medicare/provider/pdfs/0405drug_allow. pdf [Accessed 2005 May 5]
30. FDA home page [online]. Available from URL: http://www.fda.org [Accessed 2005 Jun 21]
31. Center for Medicare and Medicaid Services. Overview [online]. Available from URL: http://www.cms.hhs.gov/HistPartBDrugPricingFiles/01_overview.asp [Accessed 2006 Apr 10]
32. Niles S. Medicare market makeover. Med Ad News 2005 May; 24 (5): 4, 54-6
33. Fox P. Prescription drug benefits: cost management issues for Medicare [online]. Available from URL: http://www.cms.hhs.gov/apps/review/03_04winter/ 03_04winterpg7.pdf [Accessed 2006 Apr 5]
34. US Medicare drug plans must expedite formulary review of new medicines in 2007. www.scripnews.com. Scrip 2006 Apr 7; 3146: 14
35. Sheldon T, Cullum N, Dawson D, et al. What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patient's notes, and interviews. BMJ 2004; 329: 999-1007
36. National Institute for Health and Clinical Excellence. Final appraisal determination: donezepil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Aug 24]
37. US Pharmacopeia Convention guidelines for formulary development [online]. Available from URL: http://www.usp.org [Accessed 2006 May 11]
38. CancerBACKUP. CancerBACKUP 'Dossier of delay' reveals cancer patients waiting for potential life-saving cancer treatment. 2005 May 26 [online]. Available from URL: http://www.cancerbackup.org.uk/News/Press/ Pressreleasesstatements/2005/84975716 [Accessed 2005 May 19]
39. PhRMA. What goes into the cost of prescription drugs? [online]. Available from URL: http://www.phrma.org/files/Cost_of_Prescription_Drugs.pdf [Accessed 2006 May 11]